跳至主要內容
TradingPilot
績效
佈景主題
登入

新聞與行事曆

新聞: 截至 2026-10-09
這些標記是什麼意思

重要性是模型對已發布報導給出的 1–5 分，不是對市場的預測。

已排定事件列上的影響是公司顯著度層級（高/中由圖譜中心度與規模判定；低僅用於人工整理的次要事件），不是對波動幅度的預測。

標記為已確認的財報日期，是 Yahoo Finance 認定由公司確認的；預估表示尚未公布。未加標記的列沒有可查的出處記錄。

經濟數據發布屬於總體經濟、不歸屬任何產業，因此在任何檢視下都會保留。沒有數值的發布表示尚未公布，頁面會直說，而不是顯示為零。

涵蓋被追蹤公司的即將到來的事件；已過去的事件會歸檔，並在可得時補上結果——這些結果都經人工整理並附引用，絕不杜撰。沒有結果的歷史列會顯示「結果待定」。

閉鎖期屆滿或指數調整的列會多出一行算術——將變得可賣出的股數，或指數基金必須買進的股數，以佔流通股的比例表示——依招股說明書或指數編製方法讀出，兩個數字都在該列註明出處。它陳述的是機制，不是價格走勢。由 IPO + 180 天推算出的閉鎖期日期會一直標為預估，直到公司自己說明為止。

未來

已排定 · 今天與明天 · 行事曆更新於 2026-10-13

10月13日週二 · 今天

10月14日週三

過往

已發布 · 最新在前

9月30日週三

合作

12:00
Constellation Energy

Constellation and Amazon sign 20-year Calvert Cliffs nuclear power agreement

Constellation and Amazon announced a long-term agreement supporting investment in the Calvert Cliffs nuclear plant in Maryland, enabling more than $3 billion of infrastructure investment and about 190 megawatts of new capacity coming online between 2030 and 2032. The expansion is supported by a 20-year agreement that includes 690 megawatts of power.

文章預覽

Skip to main content Constellation and Amazon Announce 20-Year Power Purchase Agreement Adding 190 Megawatts of Nuclear Capacity at Calvert Cliffs LUSBY, MD – SEPT. 30, 2026 – Constellation (Nasdaq: CEG) and Amazon (Nasdaq: AMZN) today announced a long-term agreement that will support the continued investment in and expansion of the Calvert Cliffs Clean Energy Center , Maryland's only nuclear plant and largest source of clean energy. The agreement will enable more than $3 billion in Maryland infrastructure investment, including state-of-the-art improvements across the entire 1,790-megawatt…

AmazonConstellation Energy 開啟原文 ↗

合作

11:46
HPE

HPE wins first AMD Helios order from Vultr

HPE announced a $1.2 billion order from Vultr for AMD Helios AI Rack by HPE systems at U.S. cloud data centers. The systems combine AMD compute with HPE networking and liquid cooling for AI training and inference.

AMDHewlett Packard Enterprise 開啟原文 ↗

財報

11:32
SEC EDGAR (8-K Exhibit 99.1)

Jabil posts fiscal fourth-quarter results and fiscal 2027 outlook

Jabil reported fourth-quarter net revenue of $10.6 billion and core diluted EPS of $4.40. The CEO said fiscal 2026 revenue grew 21% and its teams supported significant growth in AI infrastructure; first-quarter fiscal 2027 net revenue is guided to $10.6 billion to $11.4 billion.

文章預覽

Exhibit 99.1 Jabil Posts Fourth Quarter and Fiscal Year 2026 Results Provides Strong Fiscal 2027 Outlook ST. PETERSBURG, Fla. – September 30, 2026 – Today, Jabil Inc. (NYSE: JBL), reported preliminary, unaudited financial results for its fourth quarter and fiscal year ended August 31, 2026. “We delivered a fourth quarter that exceeded our expectations, closing an exceptional fiscal 2026 in which we grew revenue 21%, expanded core operating margin 40 basis points and generated more than $1.5 billion in adjusted free cash flow,” said CEO Mike Dastoor. “Our…

Jabil 開啟原文 ↗

9月29日週二

合作

20:05
Applied Materials

Applied Materials and Kioxia partner on next-generation AI memory

Kioxia will join Applied Materials’ EPIC Center as an innovation partner. The companies plan joint work on memory structures, multi-chip stacking, advanced packaging and materials engineering for AI memory.

Applied MaterialsKioxia Holdings 開啟原文 ↗

合作

11:00
GlobeNewswire

Nurix achieves research milestone in Pfizer collaboration

Nurix announced a $7 million research milestone under its existing Pfizer collaboration to develop degrader antibody conjugates. The company said the achievement advances research under the agreement originally signed with Seagen.

文章預覽

Accessibility: Skip TopNav Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer Milestone reflects continued progress in collaboration to develop a novel class of degrader antibody conjugates, or DACs September 29, 2026 07:00 ET | Source: Nurix Therapeutics, Inc. Nurix Therapeutics, Inc. BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced t…

Pfizer 開啟原文 ↗

原始消息流

所有到達的消息 · 7 天